6-propyl-4-(3-trifluoromethylphenyl)-1H-pyrimidin-2-one | 871793-17-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-propyl-4-(3-trifluoromethylphenyl)-1H-pyrimidin-2-one
• 英文别名: 6-propyl-4-[3-(trifluoromethyl)phenyl]-1H-pyrimidin-2-one
• CAS: 871793-17-8
• 化学式: C₁₄H₁₃F₃N₂O
• 分子量: 282.265
• InChiKey: DIWQAWSWIGLOBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-propyl-4-(3-trifluoromethylphenyl)-1H-pyrimidin-2-one 在 三氯氧磷 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 72.33h， 生成 4-propyl-6-(3-trifluoromethylphenyl)pyrimidine-2-carbonitrile
  参考文献：
  名称：

  [EN] 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES
  [FR] DERIVES 4-PHENYLE-PYRIMIDINE-2-CARBONITRILE

  摘要：

  该发明涉及具有通式（I）或其药学上可接受的盐的4-苯基嘧啶-2-羰基衍生物。该发明还涉及包含上述衍生物的药物组合物，以及在制备适用于治疗骨质疏松症、动脉粥样硬化、炎症和免疫性疾病（如类风湿性关节炎）以及神经病理性疼痛（如神经病性疼痛）的药物中的使用。

  公开号：

  WO2005121106A1
• 作为产物：
  描述：

  3-hydroxy-1-(3-(trifluoromethyl)phenyl)hex-2-en-1-one 、 尿素 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 6-propyl-4-(3-trifluoromethylphenyl)-1H-pyrimidin-2-one
  参考文献：
  名称：

  Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors

  摘要：

  Morphing structural features of HTS-derived chemotypes led to the discovery of novel 2-cyano-pyrimidine inhibitors of cathepsin K with good pharmacokinetic profiles, for example, compound 20 showed high catK potency (IC(50) = 4 nM), >580-fold selectivity over catL and catB, and oral bioavailability in the rat of 52%. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.100

文献信息

• 4-Phenyl-Pyrimidine-2-Carbonitrile Derivatives
  申请人：Cai Jiaqiang

  公开号：US20080090813A1

  公开（公告）日：2008-04-17

  The invention relates to 4-phenyl-pyrimidine-2-carbonitrile derivatives having the general formula I wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising the derivatives as well as to the use thereof in the treatment of osteoporosis, atherosclerosis, inflammation and immune disorders, such as rheumatoid arthritis, and chronic pain, such as neuropathic pain.

  本发明涉及一种具有一般式I的4-苯基嘧啶-2-碳腈衍生物，其中每个取代基的定义如规范和权利要求所述，或其药学上可接受的盐。本发明还涉及包括这些衍生物的制药组合物以及在治疗骨质疏松症、动脉硬化、炎症和免疫性疾病（如类风湿性关节炎）以及慢性疼痛（如神经病性疼痛）中使用它们的用途。
• 4-phenyl-pyrimidine-2-carbonitrile derivatives
  申请人：N.V. Organon

  公开号：US07589095B2

  公开（公告）日：2009-09-15

  The invention relates to 4-phenyl-pyrimidine-2-carbonitrile derivatives having the general formula I wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising the derivatives as well as to the use thereof in the treatment of osteoporosis, atherosclerosis, inflammation and immune disorders, such as rheumatoid arthritis, and chronic pain, such as neuropathic pain.

  本发明涉及具有通式I的4-苯基嘧啶-2-羧腈衍生物，其中每个取代基的定义如规范和权利要求所述，或其药学上可接受的盐。本发明还涉及包含该衍生物的制药组合物以及在骨质疏松症、动脉粥样硬化、炎症和免疫紊乱（如类风湿关节炎）以及慢性疼痛（如神经病性疼痛）的治疗中使用该衍生物的用途。
• 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES
  申请人：N.V. Organon

  公开号：EP1758870A1

  公开（公告）日：2007-03-07
• US7589095B2
  申请人：——

  公开号：US7589095B2

  公开（公告）日：2009-09-15
• Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors
  作者：Zoran Rankovic、Jiaqiang Cai、Jennifer Kerr、Xavier Fradera、John Robinson、Ashvin Mistry、Emma Hamilton、George McGarry、Fiona Andrews、Wilson Caulfield、Iain Cumming、Maureen Dempster、John Waller、Paul Scullion、Iain Martin、Ann Mitchell、Clive Long、Mark Baugh、Paul Westwood、Emma Kinghorn、John Bruin、William Hamilton、Joost Uitdehaag、Mario van Zeeland、Dominique Potin、Laurent Saniere、Andre Fouquet、François Chevallier、Hortense Deronzier、Cecile Dorleans、Eric Nicolai

  DOI：10.1016/j.bmcl.2010.01.100

  日期：2010.3

  Morphing structural features of HTS-derived chemotypes led to the discovery of novel 2-cyano-pyrimidine inhibitors of cathepsin K with good pharmacokinetic profiles, for example, compound 20 showed high catK potency (IC(50) = 4 nM), >580-fold selectivity over catL and catB, and oral bioavailability in the rat of 52%. (C) 2010 Elsevier Ltd. All rights reserved.